TRANSDERMAL DELIVERY OF TETRAHYDRO-CANNABINOL

屈诺比诺在治疗厌食症和治疗癌症化疗中的恶心和频繁呕吐方面是有效的止吐药物。目前这是口服给药，并不总是有效的。一项荟萃分析研究显示，在750个疗程的口服治疗中，约65%的患者对屈诺比诺的反应较差或部分有效。因此，这种药物单次剂量大，会引起镇静、精神错乱和焦虑等副作用。这些问题可以通过经皮贴片持续给予低剂量的屈诺比诺来最小化。这种给药途径一方面减少了口服给药引起的吸收和代谢的变化，另一方面避免了肝脏首过失活，提高了生物利用度和疗效。Treateutics公司将通过体外扩散实验和药物在不相容溶剂之间的分布来估计屈诺松醇的血浆水平。在第一阶段SBIR项目中，承包商提议开发用于向该系统更安全地输送药物的屈诺比诺真皮贴片。

Dronabinol is effective as an anti-emetic in anorexia, and for treating nausea and frequent vomiting in cancer chemotherapy. This is currently administered orally, and is not always effective. A meta-analysis study revealed a poor or partial response to dronabinol in approximately 65% of 750 courses of oral therapy. Thus high single doses of this drug are administered causing side effects such as sedation, confusion, and anxiety. These problems could be minimized by the administration of sustained low doses of dronabinol via a trans-dermal patch. This route of administration will reduce the variation in absorption and metabolism, associated with oral administration and on the other hand increase the bio-availability and the efficacy by avoiding liver first-pass inactivation. Therapeutics plasma levels of dronabinol will be estimated from in vitro diffusion experiments and drug distribution between immiscible solvents. During this phase I SBIR project, the contractor proposes to develop the dronabinol dermal adhesive patch for safer delivery of drug to the system.